Library Prep Kit V3
High-confidence protein sequencing from nanogram inputs starting at 200 ng or less of protein
Other · OtherCompany source
Company profile
About Quantum-Si
Quantum-Si is pioneering the post-genomic era by making protein sequencing accessible to researchers worldwide. Founded in 2013, the company has developed the world's first next-generation protein sequencing instruments—Platinum and Platinum Pro—which deliver single-molecule, single-amino acid resolution in compact benchtop systems. By integrating biology, chemistry, and artificial intelligence, Quantum-Si empowers researchers to study proteins at an unprecedented scale and detail. The company's proprietary technology uses kinetic signatures to sequence proteins directly at the single-molecule level, providing capabilities that simplify sequencing compared to Edman degradation, dive deeper than mass spectrometry with single-molecule resolution, and detect amino acid-level changes missed by immunoassays. This approach enables precise detection of proteoforms, post-translational modifications, protein variants, and isobaric variations without relying on antibodies or complex workflows. Quantum-Si's platforms support a streamlined workflow requiring less than three hours of hands-on time and work with nanogram protein inputs (200 ng or less). The technology serves diverse applications including biomarker discovery, disease mechanism research, drug development, antibody characterization, and protein barcoding for multiplexed variant screening. The company's innovation is driving groundbreaking advancements in scientific research, therapeutic development, and clinical proteomics, with recent peer-reviewed publications demonstrating value in clinical research and pathogen/toxin detection.
Company description Quantum-Si official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Quantum-Si?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
- Academic research labs
- Biotech companies
- Pharmaceutical companies
- Research institutions
Deployment & integration
Hybrid · On Premise · Other deployment with recorded integration context.
Geographic context
MarketsSingapore · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
Expansion of Proteus Roadshow (June 2026). Partnership with Cell Signaling Technology for PTM analysis (June 2026). Publication of peer-reviewed paper in Analytical Chemistry from Stanford. Preprint publication from Naval Research Laboratory on pathogen detection.
Partnerships
Recorded partners
- Cell Signaling Technology (post-translational modification analysis partnership)
- NVIDIA (accelerated computing and AI technology)
- Stanford University (clinical proteomics research)
- U.S. Naval Research Laboratory (pathogen/toxin detection research)
- University of Virginia School of Medicine (proteoform research)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Platinum
Next-gen protein sequencer offering end-to-end solution for deeper insights with single-molecule precision
Device · On PremiseCompany source
Platinum Analysis Software
Proteomic data analysis software for Platinum Pro sequencing platform
Software · HybridCompany source
Platinum Pro
Advanced benchtop sequencer with next-gen protein sequencing delivering single-molecule resolution with real-time kinetic insights
Device · On PremiseCompany source
Protein Barcoding Kits
Characterize multiple protein variants simultaneously using protein barcodes on Platinum Pro
Other · OtherCompany source
Protein Sequencing Kits
Ready-to-sequence chips, recognizers, and aminopeptidases for deeper protein insights
Other · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Exploration of Semiconductor Chip-Based Single-Molecule Protein Sequencing for Identification of Hemoglobin Variants.Analytical chemistry · Feb 10, 2026
Next-generation protein sequencing and individual ion mass spectrometry enable complementary analysis of interleukin-6.Analytical and bioanalytical chemistry · Nov 1, 2025
Protein Sequencing with Single Amino Acid Resolution Discerns Peptides That Discriminate Tropomyosin Proteoforms.Journal of proteome research · Aug 1, 2025
Next-Generation Protein Sequencing and individual ion mass spectrometry enable complementary analysis of interleukin-6.bioRxiv : the preprint server for biology · Feb 8, 2025
Structural Dynamics of SNARE Complex Assembly in the Ribbon Synapses Observed by smFRET.Methods in molecular biology (Clifton, N.J.) · Jan 1, 2025
Analytical ab initio hessian from a deep learning potential for transition state optimization.Nature communications · Oct 14, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Single-amino acid resolution
Precision protein sequencing and variant detection
Less than 3 hours hands-on time
Simplified workflow from sample prep to analysis
200 ng or less protein input
High sensitivity with Library Prep Kit V3
Single-molecule resolution
Direct detection of proteoforms and modifications
Stanford University
Clinical proteomics research demonstrating the value of single-molecule protein sequencing
Published peer-reviewed paper in Analytical Chemistry advancing clinical research
U.S. Naval Research Laboratory
Pathogen and toxin detection using single-molecule protein sequencing for complex real-world problems
Published preprint on Chemrxiv demonstrating pathogen/toxin detection capabilities
University of Virginia School of Medicine
Protein variant detection and proteoform analysis within the TPM gene family for disease research and biomarker discovery
Successfully distinguished all major types of proteoform variation within the TPM gene family with single-amino acid resolution
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Quantum-Si
Recent articles published on Quantum-Si's official website.
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read on Quantum-SiQuantum-Si Announces the Expansion of the Proteus™ Roadshow
Read on Quantum-SiQuantum-Si Reports First Quarter 2026 Financial Results and Highlights Proteus™ Development Milestones
Read on Quantum-SiSingle-molecule protein sequencing for the characterization of proteins, purification impurities, and binding kinetics
Read on Quantum-Si07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.